Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of investors who purchased securities between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept made false and misleading statements regarding the strength of clinical trials for relacorilant and its regulatory prospects with the FDA. Investors who suffered losses are encouraged to seek lead plaintiff status by April 21, 2026.
Insider sells 20,000 CORT shares after option exercise (CORT)
A Corcept Therapeutics (CORT) insider sold 20,000 common shares on April 7, 2026, for $817,000 following a stock option exercise. This transaction and three prior sales by William Guyer in early 2026 were reported via a Rule 144 filing, confirming the transfer of securities. The event signifies a resale disclosure and the proceeds for the April 7 sale were specifically noted.
CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Corcept Therapeutics Incorporated Securities Class Action Lawsuit -- The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for Corcept Therapeutics Incorporated (NASDAQ: CORT), notifying shareholders who purchased stock between October 31, 2024, and December 30, 2025, about a securities class action lawsuit. The lawsuit alleges that Corcept made false statements regarding FDA concerns about its relacorilant drug, leading to artificial inflation of the company's stock. Shareholders have until April 21, 2026, to register to be considered for lead plaintiff.
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors
The Portnoy Law Firm has announced a class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of investors who purchased securities between October 31, 2024, and December 31, 2025. The lawsuit alleges that Corcept misrepresented the strength of the evidence supporting its relacorilant New Drug Application, despite repeated concerns from the FDA, ultimately leading to a Complete Response Letter and a significant drop in stock price. Investors have until April 21, 2026, to file a lead plaintiff motion.
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit
The Rosen Law Firm is reminding purchasers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock that they have an opportunity to lead a securities fraud lawsuit. The lawsuit alleges that Corcept misrepresented the strength of its clinical trials for relacorilant and its chances of FDA approval. Investors who purchased Corcept stock between October 31, 2024, and December 30, 2025, have until April 21, 2026, to move the court to be appointed as lead plaintiff.
Corcept Therapeutics Incorporated Sued for Securities Law
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of investors who suffered losses between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept made false and misleading statements regarding the FDA's concerns about its relacorilant hypertension treatment program, specifically the GRACE study design and expectations for NDA approval. Investors have until April 21, 2026, to seek lead plaintiff status.
CORT CLASS ACTION DEADLINE: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Corcept Therapeutics, Inc. (NASDAQ: CORT) on behalf of investors who purchased common stock between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept made false representations regarding the approval of its product candidate, relacorilant, for Cushing's syndrome, leading to a significant stock price drop after the FDA issued a Complete Response Letter. Investors have until April 21, 2026, to move the court to serve as a lead plaintiff.
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz announced that investors who suffered losses with Corcept Therapeutics Incorporated (CORT) have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that Corcept made misleading statements between October 31, 2024, and December 30, 2025, concerning FDA concerns about its relacorilant drug program. Shareholders who wish to participate must do so before the lead plaintiff deadline of April 21, 2026.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Corcept
The Rosen Law Firm is encouraging investors of Corcept Therapeutics Incorporated to secure counsel before the April 21, 2026, lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Corcept misrepresented the adequacy of clinical trials for relacorilant's New Drug Application to the FDA, leading to investor damages. The firm highlights its track record in securities class action litigation and invites affected investors to join the action.
Corcept Therapeutics Incorporated $CORT Shares Acquired by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC increased its stake in Corcept Therapeutics (NASDAQ:CORT) by 111.8% to 507,967 shares, valued at approximately $19.4 million. This comes as Corcept faces legal risks related to alleged misstatements and an FDA rejection, despite analysts maintaining a "Moderate Buy" rating with a target price of $77.67. Insider activity included a significant purchase by director G. Leonard Baker Jr. and a sale by CEO Joseph Belanoff.
CORCEPT THERAPEUTICS DEADLINE FOR LEADERSHIP is April 21, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan Fox
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Corcept Therapeutics, Inc. (NASDAQ: CORT) on behalf of investors who purchased common stock between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept made false representations regarding their relacorilant NDA's approval prospects, which were contradicted by the FDA's Complete Response Letter on December 31, 2025, causing a significant stock price drop. Investors have until April 21, 2026, to move the court to serve as lead plaintiff.
Kaplan Fox Encourages Investors of Corcept Therapeutics, Inc. (CORT) to Contact the Firm Before Lead Plaintiff Deadline on April 21, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Corcept Therapeutics, Inc. (CORT) over alleged misleading statements regarding its relacorilant NDA. Investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025, are encouraged to contact Kaplan Fox before the lead plaintiff deadline of April 21, 2026. The lawsuit stems from the FDA's Complete Response Letter for relacorilant, which caused Corcept's stock to drop significantly.
Corcept Therapeutics Faces Class Action Lawsuit
Robbins LLP has filed a class action lawsuit against Corcept Therapeutics (NASDAQ: CORT) on behalf of investors who purchased shares between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept Therapeutics made false and misleading statements regarding the development and approval prospects of its drug relacorilant, thereby inflating its stock price. This case underscores the importance of transparency for pharmaceutical companies.
Corcept Therapeutics Incorporated Class Action Reminder – Robbins LLP Encourages CORT Stockholders to Contact the Firm for Information About Their Rights
Robbins LLP is reminding stockholders of a class action lawsuit filed against Corcept Therapeutics Incorporated (NASDAQ: CORT) for investors who purchased stock between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept misled investors about the viability of its new product candidate, relacorilant, for hypercortisolism. This led to a significant drop in stock price after the FDA issued a Complete Response Letter, citing concerns about the adequacy of clinical evidence.
Corcept (CORT) Class Action Alleges Misstatements on FDA Data Concerns - Hagens Berman
Hagens Berman urges investors in Corcept Therapeutics Incorporated (CORT) who suffered significant losses to contact the firm regarding a pending securities class action. The lawsuit alleges that Corcept made misleading statements about its drug candidate relacorilant, failing to disclose FDA concerns about clinical data effectiveness, leading to a 50% stock price drop after a Complete Response Letter from the FDA. Investors have until April 21, 2026, to move for Lead Plaintiff.
CORCEPT THERAPEUTICS DEADLINE: Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on April 21, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Corcept Therapeutics, Inc. (NASDAQ: CORT) on behalf of investors who purchased common stock between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept made false representations regarding the FDA approval of its drug, relacorilant, leading to a significant stock price drop after the FDA issued a Complete Response Letter. Investors are encouraged to contact Kaplan Fox before the lead plaintiff deadline of April 21, 2026.
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics
Hagens Berman has alerted investors in Corcept Therapeutics (CORT) about a securities class action lawsuit following the FDA's rejection of their lead drug candidate, relacorilant, and a federal court patent loss. The lawsuit alleges that Corcept's management concealed repeated FDA warnings about insufficient clinical data while promoting the drug's readiness. Investors who suffered significant losses during the Class Period (October 31, 2024, to December 30, 2025) have until April 21, 2026, to move for Lead Plaintiff.
Corcept Presents Latest Data from MOMENTUM Trial at ACC.26
Corcept Therapeutics Inc. presented late-breaking data from its MOMENTUM trial at ACC.26, revealing that 27.3% of patients with resistant hypertension also had hypercortisolism. This finding, along with similar results from their CATALYST trial for difficult-to-control type 2 diabetes, suggests hypercortisolism is more prevalent than previously thought in patients whose hypertension and diabetes do not respond to standard treatments. The company hopes these results will promote increased screening for hypercortisolism to enable more accurate diagnoses and improved treatment options.
MOMENTUM Data Expands Hypercortisolism Opportunity For Corcept Investors
New MOMENTUM trial data presented by Corcept Therapeutics indicates a high prevalence of undiagnosed endogenous hypercortisolism in patients with resistant hypertension, suggesting a larger potential market for Corcept's cortisol-modulating therapies. This finding broadens the medical context for the company's focus beyond its current discussions around product pricing and valuation. Investors should monitor how Corcept integrates these findings into future strategies and whether increased R&D or commercialization efforts impact profit margins.
Kaplan Fox Alerts Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline on April 21, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Corcept Therapeutics, Inc. (NASDAQ: CORT) on behalf of investors who purchased common stock between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept made false representations regarding the approval of its drug relacorilant, leading to a significant stock drop when the FDA issued a Complete Response Letter. Investors have until April 21, 2026, to move the court to serve as a lead plaintiff.
Corcept (CORT) Class Action Alleges Misstatements on FDA Data Concerns - Hagens Berman
Hagens Berman has filed a class action lawsuit against Corcept Therapeutics (CORT), alleging the company made misleading statements regarding its drug candidate, relacorilant. The lawsuit claims Corcept failed to disclose repeated FDA warnings about insufficient clinical data, leading to a Complete Response Letter and a significant drop in stock price. Investors who purchased Corcept stock between October 31, 2024, and December 30, 2025, have until April 21, 2026, to seek lead plaintiff status.
Lost Money on Corcept Therapeutics Incorporated(CORT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Corcept Therapeutics Incorporated (CORT) on behalf of investors who suffered losses between October 31, 2024, and December 30, 2025. The lawsuit alleges that Corcept made false statements regarding its interactions with the FDA and the expected approval of its relacorilant NDA, despite the FDA expressing concerns about the drug's effectiveness assessment. Investors have until April 21, 2026, to request to be appointed as lead plaintiff.
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC is reminding investors with substantial losses in Corcept Therapeutics Incorporated (NasdaqCM: CORT) that they have until April 21, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Corcept failed to disclose material information regarding the likelihood of FDA approval for its product candidate, relacorilant, leading to a 50.4% stock price drop after the FDA issued a Complete Response Letter. Investors who purchased shares between October 31, 2024, and December 30, 2025, are affected.
A Look At Corcept Therapeutics (CORT) Valuation After FDA Approval Of Lifyorli For Platinum‑Resistant Ovarian Cancer
Corcept Therapeutics (CORT) recently received FDA approval for Lifyorli for platinum-resistant ovarian cancer, leading to recent share price volatility. Despite a 58.53% decline over the last year, the stock is currently trading at an 88.53% intrinsic discount with an analyst target of US$67.40, and the community narrative suggests it is 40% undervalued. However, its P/E ratio of 41.3x is higher than the industry average, indicating a premium valuation.
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Corcept Therapeutics Incorporated (CORT) for investors who suffered losses. The lawsuit alleges that Corcept failed to disclose concerns from the FDA regarding its relacorilant program and the GRACE trial, making their positive statements misleading. Current investors are encouraged to contact the firm by April 21, 2026, to potentially lead the lawsuit.
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP has announced that shareholders of Corcept Therapeutics Incorporated (CORT) who incurred losses have an opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that Corcept failed to disclose concerns from the FDA regarding the adequacy of the relacorilant program, specifically the design of its "GRACE" trial study. The firm encourages affected investors to contact them before the April 21, 2026, lead plaintiff deadline.
Analysts Are Bullish on Top NA Stocks: Ottobock SE & Co. KGaA (OBCKF), Corcept Therapeutics (CORT)
Two analysts have issued bullish sentiments on Ottobock SE & Co. KGaA (OBCKF) and Corcept Therapeutics (CORT). Canaccord Genuity analyst Edward Nash maintained a Buy rating on Corcept Therapeutics with a price target of $110.00, and UBS upgraded Ottobock to Buy from Neutral. The consensus for Corcept Therapeutics is a Strong Buy with an average price target of $81.00.
CORT Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Corcept Therapeutics Incorporated Securities Lawsuit -- The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) who incurred losses during the class period of October 31, 2024, to December 30, 2025. The lawsuit alleges that Corcept made false and misleading statements regarding FDA concerns about its relacorilant drug's effectiveness and the design of the GRACE study, leading to an artificial inflation of the stock price. Shareholders are encouraged to contact the firm before the lead plaintiff deadline of April 21, 2026, to potentially lead the class action.
Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally
Corcept Therapeutics (NASDAQ: CORT) experienced a significant rally in late March 2026, with shares surging over 25% following an unexpected early FDA approval of relacorilant (Lifyorli™) for platinum-resistant ovarian cancer. This approval, granted almost four months ahead of schedule, positions Corcept in the oncology market and diversifies its revenue stream amidst regulatory setbacks for its Cushing’s syndrome drug and generic threats to Korlym. The company's success highlights the potential of its selective glucocorticoid receptor antagonists and broadens its market potential into resistant hypertension.
CORT DEADLINE NOTICE: Corcept Therapeutics Incorporated Investors Encouraged to Contact Kirby McInerney LLP By April 21, 2026
Kirby McInerney LLP is reminding investors of Corcept Therapeutics Incorporated (NASDAQ:CORT) that the deadline to apply for lead plaintiff in a securities fraud class action lawsuit is April 21, 2026. The lawsuit alleges that Corcept misrepresented the strength of clinical trial data for its drug relacorilant, leading to a significant stock price drop after the FDA issued a Complete Response Letter rejecting its New Drug Application. Investors who suffered losses between October 31, 2024, and December 30, 2025, are encouraged to contact the firm.
CORT INVESTOR ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Hagens Berman has alerted Corcept Therapeutics (CORT) investors about a securities class action lawsuit following the FDA's rejection of their lead drug candidate, relacorilant, and a significant stock price drop. The lawsuit alleges that Corcept's management concealed repeated FDA warnings about insufficient data, leading to a "Complete Response Letter" from the FDA. Investors who purchased CORT stock between October 31, 2024, and December 30, 2025, have until April 21, 2026, to move for Lead Plaintiff status.
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $73
Piper Sandler has reiterated its Buy rating for Corcept Therapeutics (CORT.US) and maintained its price target at $73. This indicates a continued positive outlook on the company's stock performance from the analyst firm.
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors
The Portnoy Law Firm has announced a class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of investors who purchased securities between October 31, 2024, and December 31, 2025. The lawsuit alleges that Corcept misrepresented the strength of the evidence supporting its relacorilant New Drug Application and concealed repeated concerns raised by the FDA, ultimately leading to a Complete Response Letter and a significant drop in stock price. Investors have until April 21, 2026, to file a lead plaintiff motion.
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors
The Portnoy Law Firm has announced a class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of investors who purchased securities between October 31, 2024, and December 31, 2025. The lawsuit alleges that Corcept misrepresented the Strong evidence supporting its new drug application for relacorilant, despite repeated concerns from the FDA. This ultimately led to a Complete Response Letter from the FDA and a significant drop in Corcept's stock price.
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of Corcept Therapeutics Incorporated (NASDAQ: CORT) about a class action lawsuit alleging securities fraud. The lawsuit claims Corcept made false and misleading statements regarding the viability of its product candidate, relacorilant, specifically that the FDA deemed its clinical data inadequate despite the company claiming it was "approaching approval." Investors who purchased the company's securities between October 31, 2024, and December 30, 2025, are encouraged to contact the firm to discuss their rights before April 21, 2026.
Corcept Therapeutics (CORT) climbs 19.7% as Lifyorli gets FDA OK
Corcept Therapeutics (CORT) shares surged by 19.7% after the U.S. Food and Drug Administration (FDA) approved its drug Lifyorli (miricorilant) for the treatment of endogenous Cushing’s syndrome. This approval marks a significant milestone for the company, as Lifyorli is the first and only non-steroidal glucocorticoid receptor blocker to receive FDA clearance for this condition. The drug is expected to launch in the third quarter of 2026.
Over a quarter of resistant hypertension patients had hypercortisolism
Corcept Therapeutics presented data from its MOMENTUM trial at the American College of Cardiology Annual Scientific Session, revealing that 27.3% of patients with resistant hypertension had hypercortisolism. This finding, along with results from their CATALYST trial for difficult-to-control type 2 diabetes, suggests that hypercortisolism is more common than previously assumed in patients whose conditions do not respond to standard treatments. The company emphasizes the importance of increased screening for hypercortisolism to enable more accurate diagnoses and improved personalized care.
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
Corcept Therapeutics presented late-breaking data from its MOMENTUM trial at the ACC 2026, revealing that 27.3% of patients with resistant hypertension had hypercortisolism. This finding complements results from their CATALYST trial and suggests that hypercortisolism is more common than previously thought in patients whose hypertension and diabetes are difficult to control. The company emphasizes the importance of screening for hypercortisolism to enable more personalized and effective treatment options.
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Hagens Berman has alerted investors in Corcept Therapeutics (CORT) about a securities class action lawsuit following the FDA's rejection of its drug candidate, relacorilant, and a court patent loss. The lawsuit alleges that Corcept's management concealed repeated FDA warnings about insufficient data, leading to a significant drop in stock price. Investors who suffered losses have until April 21, 2026, to move for Lead Plaintiff.
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 Deadline
Hagens Berman has issued an alert to investors of Corcept Therapeutics (CORT) regarding a securities class action lawsuit. The lawsuit alleges that Corcept's management concealed repeated FDA warnings about insufficient data for its lead drug candidate, relacorilant, while misleadingly promoting its readiness. Following the FDA's rejection of relacorilant, Corcept's stock plummeted by 50%, wiping out nearly $2.5 billion in market capitalization. The deadline for investors to move for Lead Plaintiff is April 21, 2026.
Corcept Therapeutics (CORT) CEO trust sells 26,198 company shares
Corcept Therapeutics' CEO Joseph K. Belanoff, through a revocable living trust, sold 26,198 shares of common stock at a weighted average price of $50.0735 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2024. Following the sale, the trust-related holdings for Belanoff amount to 2,918,326 shares of Corcept Therapeutics common stock.
Corcept Therapeutics (CORT) climbs 19.7% as Lifyorli gets FDA OK
Corcept Therapeutics (CORT) shares surged by 19.7% following the FDA's approval of its drug, Lifyorli (miricorilant), for Cushing's syndrome. This approval makes Lifyorli the first FDA-approved non-steroidal glucocorticoid receptor antagonist for the endogenous hypercortisolism condition. The company plans to launch the drug in the third quarter of 2026.
Is Corcept Therapeutics (CORT) Pricing Reflect Its Recent Share Rebound And DCF Upside Potential
Corcept Therapeutics (CORT) has seen a recent share rebound, with its stock moving up 13.1% in the last week, despite a 32.0% decline over the past year. A Discounted Cash Flow (DCF) analysis suggests the company is significantly undervalued, trading at an 88.4% discount to its estimated intrinsic value of $332.45 per share. Additionally, while its P/E ratio of 41.75x is above industry averages, it screens as modestly undervalued compared to Simply Wall St's proprietary Fair Ratio of 43.08x.
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit
The Rosen Law Firm reminds investors who purchased Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, of the April 21, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Corcept misrepresented the strength of clinical trials for relacorilant and its New Drug Application (NDA) to the FDA, despite the FDA raising concerns about the evidence. Investors suffered damages when the true details came to light.
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss
Hagens Berman has alerted Corcept Therapeutics (CORT) investors to a securities class action lawsuit following a significant drop in stock price after the FDA issued a Complete Response Letter for Corcept's drug candidate, relacorilant. The lawsuit alleges that Corcept's management concealed FDA warnings regarding insufficient clinical data while promoting the drug's readiness. Investors who purchased Corcept stock between October 31, 2024, and December 30, 2025, have until April 21, 2026, to seek lead plaintiff status.
Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline - Contact Kaplan Fox Before April 21, 2026
Kaplan Fox & Kilsheimer LLP is reminding investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) about a securities class action lawsuit deadline of April 21, 2026. The lawsuit alleges that Corcept made false representations regarding their relacorilant NDA, which was ultimately not approved by the FDA, causing a significant drop in stock price. Investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025, are encouraged to contact Kaplan Fox.
Wolfe Research Upgrades Corcept Therapeutics (CORT) to Peer Perf
Wolfe Research has upgraded Corcept Therapeutics (CORT) from 'Underperform' to 'Peer Perform', a change made by analyst Kalpit Patel on March 26, 2026, with no accompanying price target adjustment. This upgrade introduces a positive sentiment for Corcept Therapeutics, which is a commercial-stage pharmaceutical company focused on developing medications for metabolic, oncologic, and neuropsychiatric disorders. The average one-year price target from 5 analysts is $67.40, implying a 71.31% upside from its current price, and the average brokerage recommendation indicates an "Outperform" status.
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics
Hagens Berman has alerted Corcept Therapeutics (CORT) investors about a securities class action lawsuit following an FDA rejection and a patent loss. The lawsuit alleges that Corcept's management concealed repeated FDA warnings about insufficient data for their drug candidate, relacorilant, while falsely touting its pipeline readiness. Investors who suffered losses are urged to contact Hagens Berman, with a deadline of April 21, 2026, to move for Lead Plaintiff.
Corcept Therapeutics (CORT) Is Up 21.5% After First-in-Class Lifyorli Cancer Approval - Has The Bull Case Changed?
Corcept Therapeutics saw its stock rise 21.5% following FDA approval of Lifyorli (relacorilant) for platinum-resistant ovarian cancer, marking the first selective glucocorticoid receptor antagonist in oncology. While this approval diversifies Corcept's revenue beyond Korlym, legal and regulatory challenges related to hypercortisolism treatment and patent issues remain significant for the company's investment outlook. Analysts have varying revenue and earnings forecasts, indicating a divided view on the company's future prospects and the impact of Lifyorli's success.
Corcept Therapeutics (CORT) Climbs 19.7% as Lifyorli Gets FDA OK
Corcept Therapeutics Inc. (NASDAQ:CORT) shares climbed by 19.7% after its ovarian cancer treatment, Lifyorli, received FDA approval. The approval was based on a successful clinical trial that showed a significant reduction in death risk and disease progression for patients with platinum-resistant ovarian cancer treated with Lifyorli in combination with nab-paclitaxel. This marks a significant development for the company and its oncology pipeline.
